Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: A drug from the PCSK9 inhibitor group, already registered for treating elevated lipids. It is available to patients who have had a myocardial infarction and, with existing medications, have excessively high LDL cholesterol. In the context of this study, the drug can be given to patients who have not had a myocardial infarction but are at a high risk of it.
Main Inclusion Criteria: Patients aged 40-80 years with LDL cholesterol in the range of 1.8-4.9 (with or without statins), who do not have known blood vessel blockages and have at least two of the following conditions: high blood pressure, diabetes, overweight, smoking.
Status: Enrolling patients
Start of patient enrollment: January 2024
Planned completion of new patient enrollment: July 2024
